Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder

• Status: Completed
• Trial end date: 2006-03-01

Summary

The purposes of this study are to determine:

• The effectiveness of olanzapine as compared to quetiapine in treating and preventing the recurrence of a variety of symptoms of schizophrenia and schizoaffective disorder in patients who are obese or overweight.

• The safety of olanzapine as compared to quetiapine.

• Phase: Phase 4

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Olanzapine; Quetiapine Fumarate